DEA Approves THC Medicine for Schedule 2

The Drug Enforcement Administration (DEA) has given approval to a pharmaceutical THC product.

Syndros.

After waiting roughly two years, the pharmaceutical drug company Insys has received approval from the DEA for their product Syndros. Syndros, according to Westword, is “an oral remedy containing THC”, which has been approved to treat nausea and vomiting, particular for cancer patients going through chemotherapy.

The DEA’s approval of Syndros flies contrary to their stance of cannabis being a schedule 1 drug, meaning it has no known medical value. That can’t, however, be true if one of its primary compounds has been proven to being medically beneficial, and has been approved for medical use.

Read moreDEA Approves THC Medicine for Schedule 2

After Months of Public and Legal Pressure, DEA Removes Marijuana Misinformation from Website

The Drug Enforcement Administration (DEA) has removed marijuana misinformation from their website following months of public and legal pressure.

After months of public pressure, and a legal request by the nonprofit medical cannabis advocacy group Americans for Safe Access, the DEA has removed factually inaccurate information about marijuana from their website.

As part of the legal request, Americans for Safe Access argued that there was over 25 incorrect statements on the DEA’s website about cannabis, which violates the Information Quality Act, which prohibits government agencies from providing false information to the public, and requires them to respond to requests for correction of information within 60 days.

Read moreAfter Months of Public and Legal Pressure, DEA Removes Marijuana Misinformation from Website